Related Experiment Videos
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction
Insights
The Aspirin Myocardial Infarction Study found that daily aspirin did not reduce total mortality in patients who had survived a heart attack. Aspirin also increased gastrointestinal side effects, leading to no recommendation for its routine use post-myocardial infarction.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- Post-myocardial infarction (MI) patients face elevated risks of mortality and recurrent events.
- Aspirin's antiplatelet properties suggest potential benefits in secondary prevention.
- Previous studies indicated aspirin's efficacy in reducing cardiovascular events.
Purpose of the Study:
- To determine if regular aspirin administration reduces total mortality in patients post-myocardial infarction (MI).
- To evaluate cause-specific mortality, nonfatal cardiovascular events, and adverse effects of aspirin in this population.
Main Methods:
- The Aspirin Myocardial Infarction Study (AMIS) was a randomized, double-blind, placebo-controlled trial.
- 4,524 participants aged 30-69 with a history of MI were randomized to 1g aspirin daily or placebo.
- Follow-up extended over a three-year period to assess mortality and morbidity.
Main Results:
- Total mortality was slightly higher in the aspirin group (9.6%) compared to placebo (8.8%) over three years.
- Nonfatal myocardial infarction rates were lower with aspirin (6.3%) versus placebo (8.1%).
- Gastrointestinal symptoms (ulcer, gastritis) were significantly more frequent in the aspirin group (23.7%) than placebo (14.9%).
Conclusions:
- Aspirin did not demonstrate a significant reduction in total mortality for patients who had experienced a myocardial infarction.
- The increased incidence of gastrointestinal side effects outweighs potential benefits in this patient group.
- Routine aspirin use is not recommended for patients following a myocardial infarction based on AMIS findings.
Abstract:
The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period. Cause-specific mortality, nonfatal events, and side effects were also evaluated. Over a 13-month period, 4,524 persons between the ages of 30 and 69 years were randomized to either 1 g of aspirin per day (2,267 persons) or placebo (2,257 persons). High levels of patient compliance to study protocol were indicated by various measures. Total mortality during the entire follow-up period was 10.8% in the aspirin group and 9.7% in the placebo group. Three-year total mortality was 9.6% in the aspirin group and 8.8% in the placebo group. The percentage of definite nonfatal MI was 8.1% in the placebo group and 6.3% in the aspirin group. Coronary incidence (coronary heart disease mortality or definite nonfatal MI) was 14.1% in the aspirin group and 14.8% in the placebo group. Symptoms suggestive of peptic ulcer, gastritis, or erosion of gastric mucosa occurred in 23.7% of the aspirin group and 14.9% in the placebo group. Based on AMIS results, aspirin is not recommended for routine use in patients who have survived an MI.